JNJ Stock Has a New Growth Story, but One Business Needs to Catch Up

Johnson and Johnson just posted a quarter where one business charged ahead while another quietly stalled, and which side wins out will determine whether the stock earns its premium valuation over rivals like Merck and AbbVie.